JPRN-UMIN000019122Completed未知
A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer - A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer
Juntendo Nerima Hospital0 sites76 target enrollmentStarted: September 26, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 76
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- Female
Inclusion Criteria
- Not provided
Exclusion Criteria
- •receipt of any agent that could affect the study results (such as an antiemetic, steroid, or pimozide) before the start of chemotherapy; symptomatic brain metastasis; gastro-intestinal obstruction or any other condition that could provoke nausea and vomiting; and a known allergy or severe reaction to any of the study drugs.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)Salivary gland cancerMedDRA version: 20.0Level: PTClassification code 10061497Term: Salivary gland neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000314-38-ITEORTC AISBL/IVZW220
Recruiting
Phase 2
A study in HIV infected blood cancer patients to know to test two types of chemotherapy regimen. Patients will be divided in two equal groups for testing purpose.CTRI/2020/10/028220Tata Memorial Hospital Research Administrative Council
Recruiting
Phase 2
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in patients with local limited small cell lung cancer2024-513433-20-00Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR105
Active, not recruiting
Phase 1
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)Salivary gland cancerMedDRA version: 17.0Level: PTClassification code 10061934Term: Salivary gland cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000314-38-FREuropean Organisation for Research and Treatment of Cancer (EORTC)452
Active, not recruiting
Phase 1
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)Salivary gland cancerMedDRA version: 20.0Level: PTClassification code 10061934Term: Salivary gland cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000314-38-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)220